Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $53 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Dyne Therapeutics, maintaining a price target of $53.
September 23, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on Dyne Therapeutics, maintaining a price target of $53, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $53 by Piper Sandler suggests a positive outlook for Dyne Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100